Navigation Links
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
Date:12/14/2008

) versus 1% (Grade 3/4 0%) * Stomatitis: 52% (Grade 3/4 11%) versus 14% (Grade 3/4 1%) * Alopecia: 48% versus 45% * Asthenia: 29% (Grade 3/4 4%) versus 20% (Grade 3/4 3%) * Nausea: 28% (Grade 3/4 1%) versus 22% (Grade 3/4 <1%) * Fatigue: 20% (Grade 3/4 3%) versus 15% (Grade 3/4 2%)

The study was sponsored by Ortho Biotech Oncology Research & Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

About DOXIL(R)

DOXIL is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum based therapy. DOXIL in combination with VELCADE(R) (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

    IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:

Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution

     * The use of DOXIL may lead to cardiac toxicity. Myocardial damage may
       lead to congestive heart failure and may occur as the total cumulative
       dose of doxorubicin HCl approaches 550 mg/m2
         - Prior use of other anthracyclines or anthracenediones should be
           included in calculations of total cumulative dose
         - Cardiac toxicity may also occur at lower cumulative doses (400
           mg/m2) in patients with prior mediastinal irradiation or who are
           receiving concurrent cyclophosphamide therapy
     * Acute infusion-related reactions including, but not limited to,
       flushing, shortness of breath, facial swelling, headache, chills, back
       pain, tightness in
'/>"/>
SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Major deCODE-led Study Underscores Role of the Brain in Obesity
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
4. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
5. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
6. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
9. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 Harwood Feffer LLP ... board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or ... board has breached its fiduciary duties to shareholders. ... press release announcing results from its first Phase 3 ... release disclosed that in the trial, Rhopressa failed to ...
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... AUSTIN, Texas , April 27, 2015 ... solutions company focused on gynecologic disease, announced ... financial results after the market close on ... investor conference call and webcast at 4:30pm ... 2015 at 4:30pm Eastern/1:30pm Pacific Domestic: , ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
(Date:4/27/2015)... April 27, 2015 Array Health ... technology, has announced that Lance Hood, senior director of ... fourth annual Direct-to-Consumer Health Care Marketing Summit ... David Smith, Partner and Director of Payer Services, Leavitt ... care consumerism – through a retail/e-commerce perspective – and ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is a ... Philadelphia for his upcoming concert on Sunday, June 21st. ... thrill his countless North American fans again in 2015 when ... his "Out There" tour. He will be performing in ... to listen to this legendary performer for the first time ...
(Date:4/27/2015)... Thanks to a $7.5 million grant ... half-dozen institutions, including American University, will operate in a ... and behavioral research aimed at ending the AIDS epidemic. ... with HIV or AIDS, according to the latest statistics. ... population over the age of 13 was living with ...
(Date:4/27/2015)... Angeles, CA (PRWEB) April 27, 2015 The ... has been to connect clients of personal injury attorneys with ... network of doctors has seen steady growth throughout their history ... Charles E. Richardson, DC and his team in the ... including a medical doctor and massage therapist, patients can find ...
(Date:4/27/2015)... April 27, 2015 Sitting or standing for ... and feel tired, and for those whose occupation requires them ... and taxi cab drivers, or to be on their feet ... the discomfort can be more severe and longer lasting. These ... syndrome. Dr. Madaiah Revana of Northeast Houston Vein Center is ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Paul McCartney Presale Tickets at Wells Fargo Center in Philadelphia: Ticket Down Slashes Paul McCartney Ticket Prices in Philadelphia at the Wells Fargo Center 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3
... Feb. 26 AIDS Action congratulates Jeffrey Crowley, an ... health care and HIV/AIDS for his appointment as Director ... He joins a well-respected and dedicated team in the ... and reports to Director Melody Barnes who has a ...
... inhibit both normal and virulent strains, study finds ... Combination treatment with two FDA-approved drugs shows promise ... study shows. , In laboratory tests, researchers at ... National Institute of Allergy and Infectious Diseases found ...
... The number of Americans traveling abroad for healthcare is ... trend as the recession worsens and more Americans are left ... to the Deloitte Centre for Health Solutions, the number of ... million in 2010 and 15.75 million by 2017. The $16 ...
... Ignagni, President and CEO of America,s Health Insurance Plans, ... President,s budget:"Today,s budget submission sends a signal to the ... health care. We applaud the President for laying ... to put our nation on a path towards comprehensive ...
... Consultancy, is pleased to announce the launch of a further nine ... listings to relevant specialist industries. , ... (PRWEB) February ... & Marketing Consultancy , is pleased to announce the launch of ...
... RALEIGH, N.C., Feb. 26 Arbor Pharmaceuticals, a ... that the company has launched XYLAREX - a ... otitis media (middle ear,infections). XYLAREX is a ... reduce the number of ear infections children experience. ...
Cached Medicine News:Health News:AIDS Action Applauds President on Appointment of Jeffrey Crowley as Director of National AIDS Policy 2Health News:Antibiotic Combo Fights Resistant TB 2Health News:Americans Will Soon Have Medical Butlers to Assist in Medical Tourism Research 2Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
Endoscopes...
Short system ventriculoscope for free hand use....
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
Medicine Products: